BioPharmSignal logoBioPharmSignal

Biotech News

Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption

PLUS THERAPEUTICS, Inc. (PSTV)PLUS THERAPEUTICS, Inc.Commercial

New dedicated billing code facilitates payer reimbursement, supports clinician adoptions, and enables national utilization tracking HOUSTON, April 07, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing

Related news

PSTVPLUS THERAPEUTICS, Inc.2026-06-04 11:30 EST

Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory

SNDXSyndax Pharmaceuticals2026-06-01 11:00 EST

Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026

GERNGeron2026-07-22 20:01 EST

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GERNGeron2026-07-14 20:26 EST

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

TEVATeva Pharmaceutical Industries2026-06-04 12:30 EST

Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®

FATEFate Therapeutics2026-07-09 12:30 EST

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

FATEFate Therapeutics2026-07-06 12:30 EST

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

NRIXNurix Therapeutics2026-06-11 11:00 EST

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

NRIXNurix Therapeutics2026-07-21 20:01 EST

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

KYMRKymera2026-06-12 11:00 EST

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

View all latest news

PLUS THERAPEUTICS, Inc.

PLUS Therapeutics is an oncology company focused on radiotherapeutics and targeted treatment delivery for cancer. Its story is built around the use of radiation-based approaches to address hard-to-treat tumors.

Recent company news

PSTVPLUS THERAPEUTICS, Inc.2026-06-04 11:30 EST

Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory

PSTVPLUS THERAPEUTICS, Inc.2026-05-26 11:30 EST

Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases

PSTVPLUS THERAPEUTICS, Inc.2026-05-19 11:30 EST

Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology

PSTVPLUS THERAPEUTICS, Inc.2026-05-15 20:05 EST

Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

PSTVPLUS THERAPEUTICS, Inc.2026-05-08 11:30 EST

Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases

Stock data

Close
3.87 USD
Market cap
37.65M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States